• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对大量患有严重肝脏疾病的囊性纤维化患者进行分析表明,其肺功能下降与普通囊性纤维化人群并无显著差异。

Analysis of a large cohort of cystic fibrosis patients with severe liver disease indicates lung function decline does not significantly differ from that of the general cystic fibrosis population.

机构信息

School of Medicine, Marsico Lung Institute, UNC Cystic Fibrosis Research Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.

Department of Pulmonology, Division of Pulmonary and Critical Care Medicine, School of Medicine, The University of Kansas, Kansas City, Kansas, United States of America.

出版信息

PLoS One. 2018 Oct 11;13(10):e0205257. doi: 10.1371/journal.pone.0205257. eCollection 2018.

DOI:10.1371/journal.pone.0205257
PMID:30307979
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6181334/
Abstract

Previous reports of lung function in cystic fibrosis (CF) patients with liver disease have shown worse, similar, or even better forced expiratory volume in 1 second (FEV1), compared to CF patients without liver disease. Varying definitions of CF liver disease likely contribute to these inconsistent relationships reported between CF lung function and liver disease. We retrospectively evaluated spirometric data in 179 subjects (62% male; 58% Phe508del homozygous) with severe CF liver disease (CFLD; defined by presence of portal hypertension due to cirrhosis). FEV1 values were referenced to both a normal population (FEV1% predicted) and CF population (CF-specific FEV1 percentile). We utilized a linear mixed model with repeated measures to assess changes in lung function (before and after diagnosis of CFLD), relative to both the normal and CF populations. At diagnosis of CFLD, the mean FEV1 was 81% predicted, or at the 53rd percentile referenced to CF patients without CFLD. There was a significant difference in post-CFLD slope compared to pre-CFLD slope (post-pre) using FEV1% predicted (-1.94, p-value < 0.0001). However, there was insignificant evidence of this difference using the CF-specific FEV1 percentile measure (-0.99, p-value = 0.1268). Although FEV1% predicted values declined in patients following CFLD diagnosis, there was not significant evidence of lung function decline in CF-specific FEV1 percentiles. Thus, the observed study cohort indicates diagnosis of severe CFLD was not associated with worsened CF lung disease when compared to a large CF reference population.

摘要

先前关于患有肝病的囊性纤维化 (CF) 患者的肺功能报告显示,与无肝病的 CF 患者相比,其 1 秒用力呼气量 (FEV1) 更差、相似甚至更好。CF 肝病的不同定义可能导致 CF 肺功能与肝病之间报告的这些不一致关系。我们回顾性评估了 179 例严重 CF 肝病 (CFLD;定义为肝硬化引起的门静脉高压) 患者的肺功能数据 (62%为男性;58%为纯合子 Phe508del)。FEV1 值参考正常人群 (FEV1%预测值) 和 CF 人群 (CF 特有的 FEV1 百分位数)。我们使用具有重复测量的线性混合模型来评估肺功能的变化 (在诊断 CFLD 之前和之后),相对于正常人群和 CF 人群。在诊断为 CFLD 时,FEV1 的平均值为预测值的 81%,或在无 CFLD 的 CF 患者中参考 CF 特有的 FEV1 百分位数为第 53 百分位。与 CFLD 前斜率相比,CFLD 后斜率 (后-前) 有显著差异,使用 FEV1%预测值 (-1.94,p 值 < 0.0001)。然而,使用 CF 特有的 FEV1 百分位数测量值则没有这种差异的证据 (-0.99,p 值 = 0.1268)。尽管在 CFLD 诊断后 FEV1%预测值下降,但 CF 特有的 FEV1 百分位数并没有显著证据表明肺功能下降。因此,观察到的研究队列表明,与大型 CF 参考人群相比,严重 CFLD 的诊断与 CF 肺部疾病的恶化无关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1f0/6181334/7363247647eb/pone.0205257.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1f0/6181334/7363247647eb/pone.0205257.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1f0/6181334/7363247647eb/pone.0205257.g001.jpg

相似文献

1
Analysis of a large cohort of cystic fibrosis patients with severe liver disease indicates lung function decline does not significantly differ from that of the general cystic fibrosis population.对大量患有严重肝脏疾病的囊性纤维化患者进行分析表明,其肺功能下降与普通囊性纤维化人群并无显著差异。
PLoS One. 2018 Oct 11;13(10):e0205257. doi: 10.1371/journal.pone.0205257. eCollection 2018.
2
Outcomes of patients with cystic fibrosis undergoing lung transplantation with and without cystic fibrosis-associated liver cirrhosis.囊性纤维化患者行肺移植术的结果,伴有和不伴有囊性纤维化相关的肝硬化。
Clin Transplant. 2012 Jan-Feb;26(1):34-41. doi: 10.1111/j.1399-0012.2010.01395.x. Epub 2011 Jan 28.
3
Controlled attenuation parameter: A measure of hepatic steatosis in patients with cystic fibrosis.受控衰减参数:囊性纤维化患者肝脂肪变性的测量指标。
J Cyst Fibros. 2019 Mar;18(2):280-285. doi: 10.1016/j.jcf.2018.11.004. Epub 2018 Dec 1.
4
Aspartate aminotransferase to platelet ratio and fibrosis-4 as biomarkers in biopsy-validated pediatric cystic fibrosis liver disease.天门冬氨酸氨基转移酶与血小板比值及纤维化-4 作为肝活检证实的儿童囊性纤维化肝病的生物标志物。
Hepatology. 2015 Nov;62(5):1576-83. doi: 10.1002/hep.28016. Epub 2015 Sep 28.
5
Prevalence and characteristics of cystic fibrosis liver disease: a study highlighting the lack of histological diagnosis.囊性纤维化肝病的流行情况和特征:一项突出组织学诊断缺乏的研究。
Clin Res Hepatol Gastroenterol. 2022 Nov;46(9):101977. doi: 10.1016/j.clinre.2022.101977. Epub 2022 Jun 27.
6
A Multidisciplinary Approach to Pretransplant and Posttransplant Management of Cystic Fibrosis-Associated Liver Disease.多学科方法在囊性纤维化相关肝病的移植前和移植后的管理。
Liver Transpl. 2019 Apr;25(4):640-657. doi: 10.1002/lt.25421. Epub 2019 Mar 20.
7
Liver disease in adult patients with cystic fibrosis: a frequent and independent prognostic factor associated with death or lung transplantation.成人囊性纤维化患者的肝脏疾病:与死亡或肺移植相关的常见且独立的预后因素。
J Hepatol. 2011 Dec;55(6):1377-82. doi: 10.1016/j.jhep.2011.03.028. Epub 2011 May 19.
8
Genetic modifiers of liver disease in cystic fibrosis.囊性纤维化肝病的基因修饰因子
JAMA. 2009 Sep 9;302(10):1076-83. doi: 10.1001/jama.2009.1295.
9
Gamma-glutamyl transpeptidase-to-platelet ratio as a biomarker of liver disease and hepatic fibrosis severity in paediatric Cystic Fibrosis.γ-谷氨酰转肽酶/血小板比值作为儿童囊性纤维化肝病和肝纤维化严重程度的生物标志物。
J Cyst Fibros. 2022 Mar;21(2):236-242. doi: 10.1016/j.jcf.2021.10.014. Epub 2021 Dec 23.
10
The natural history of cystic fibrosis liver disease a prospective cohort study.囊性纤维化肝病的自然史:一项前瞻性队列研究。
J Cyst Fibros. 2023 Nov;22(6):1054-1061. doi: 10.1016/j.jcf.2023.07.002. Epub 2023 Jul 24.

引用本文的文献

1
Genetic modifiers of body mass index in individuals with cystic fibrosis.囊性纤维化患者体重指数的遗传修饰物。
Am J Hum Genet. 2024 Oct 3;111(10):2203-2218. doi: 10.1016/j.ajhg.2024.08.004. Epub 2024 Sep 10.
2
Pleiotropic modifiers of age-related diabetes and neonatal intestinal obstruction in cystic fibrosis.囊性纤维化中与年龄相关的糖尿病和新生儿肠梗阻的多效修饰因子。
Am J Hum Genet. 2022 Oct 6;109(10):1894-1908. doi: 10.1016/j.ajhg.2022.09.004.
3
Role of transient elastography and APRI in the assessment of pediatric cystic fibrosis liver disease.

本文引用的文献

1
Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis.囊性纤维化患者严重肝病伴门静脉高压的特征
Clin Gastroenterol Hepatol. 2016 Aug;14(8):1207-1215.e3. doi: 10.1016/j.cgh.2016.03.041. Epub 2016 Apr 5.
2
Liver disease in cystic fibrosis.囊性纤维化中的肝脏疾病
Prz Gastroenterol. 2014;9(3):136-41. doi: 10.5114/pg.2014.43574. Epub 2014 Jun 26.
3
Liver disease in cystic fibrosis: an update.囊性纤维化中的肝脏疾病:最新进展
瞬时弹性成像和APRI在小儿囊性纤维化肝病评估中的作用。
Can Liver J. 2021 Feb 24;4(1):23-32. doi: 10.3138/canlivj-2020-0008. eCollection 2021 Winter.
4
Assessment of Selected Parameters of Liver Fibrosis and Inflammation in Patients with Diagnosed Cystic Fibrosis.评估诊断为囊性纤维化患者的肝纤维化和炎症的选定参数。
Mediators Inflamm. 2020 Mar 25;2020:5696185. doi: 10.1155/2020/5696185. eCollection 2020.
5
Strong toll-like receptor responses in cystic fibrosis patients are associated with higher lung function.囊性纤维化患者中强烈的 toll 样受体反应与更高的肺功能相关。
J Cyst Fibros. 2020 Jul;19(4):608-613. doi: 10.1016/j.jcf.2019.11.009. Epub 2019 Dec 5.
Hepat Mon. 2013 Aug 14;13(8):e11215. doi: 10.5812/hepatmon.11215.
4
The influence of genetics on cystic fibrosis phenotypes.遗传对囊性纤维化表型的影响。
Cold Spring Harb Perspect Med. 2012 Dec 1;2(12):a009548. doi: 10.1101/cshperspect.a009548.
5
Lung function decline from adolescence to young adulthood in cystic fibrosis.囊性纤维化患者从青少年到成年早期的肺功能下降。
Pediatr Pulmonol. 2012 Feb;47(2):135-43. doi: 10.1002/ppul.21526. Epub 2011 Aug 24.
6
Outcome in cystic fibrosis liver disease.囊性纤维化肝病的转归。
Am J Gastroenterol. 2011 Jan;106(1):104-9. doi: 10.1038/ajg.2010.316. Epub 2010 Aug 24.
7
Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function.定量评估环境和遗传因素对囊性纤维化肺功能变异的相对贡献。
J Pediatr. 2010 Nov;157(5):802-7.e1-3. doi: 10.1016/j.jpeds.2010.05.018. Epub 2010 Jun 30.
8
Genetic modifiers of liver disease in cystic fibrosis.囊性纤维化肝病的基因修饰因子
JAMA. 2009 Sep 9;302(10):1076-83. doi: 10.1001/jama.2009.1295.
9
Heritability of lung disease severity in cystic fibrosis.囊性纤维化肺病严重程度的遗传力。
Am J Respir Crit Care Med. 2007 May 15;175(10):1036-43. doi: 10.1164/rccm.200608-1164OC. Epub 2007 Mar 1.
10
Pulmonary prognosis in cystic fibrosis patients with liver disease.患有肝脏疾病的囊性纤维化患者的肺部预后
J Pediatr. 2006 Jul;149(1):144; author reply 144-5. doi: 10.1016/j.jpeds.2005.12.018.